INTRODUCTION
approximately 20 g were used. The mice were maintained under a 12/12-h dark/light cycle, and food and water were available ad libitum. All animal procedures were conducted in accordance with NIH Guidelines for the Use of Laboratory Animals. In order to reduce the number of animals, we did not use a separate control group for cocaine-induced sensitization. The mice were given 20 mg/kg cocaine-HCl dissolved in 0.9% NaCl intraperitoneally (Belgopia, Louvain-LaNeuve, Belgium) for 5 consecutive days. Locomotor activity was measured after the first (day 1) and last (day 5) treatments. Injections on days 2, 3, and 4 were administered in their home cages. One week after the last treatment, another dose of cocaine was given, and locomotor activity was measured to confirm that the sensitized state was maintained (day 13). The animals were then split into four groups based on locomotor activity on that day, in a manner in which the mean activity for each group was similar. Allocation of a specific drug to each group was determined randomly. Drug treatments began 3 days later, and the animals were given clozapine (5 mg/kg), fluoxetine (10 mg/kg), haloperidol (2 mg/kg), or vehicle (0.3% tartaric acid, pH adjusted to 5.0) for 5 consecutive days. After a 3-day washout period, the animals were finally challenged with the same dose of cocaine, and their locomotor activities were measured (day 23) (Figure 1 ).
Measurement of locomotor activity
Locomotor activity was measured in a sound-attenuated test room, using a home-cage video tracking apparatus (Activity Monitor Ver. 5.0, MED-Associates, St. Albans, VT, USA). Mice were placed on the test room 3 h before the test to acclimate the animals to the testing environment. Each animal was placed in a transparent acrylic box (23×21×21 cm), and its distance traveled was measured for 30 min in 5-min time block ('pre-cocaine'). Then, the animal was injected with cocaine (20 mg/kg) and distance traveled was measured for another 60 min in the same way ('post-cocaine'). Locomotor activity was measured during the light phase of the day (12:00-20:00 h).
Statistical analysis
Data were analyzed using analysis of variance (ANOVA) with post-hoc Duncan's test, or the paired t-test (two-tailed). P<0.05 was statistically significant. The software was SPSS ver 19 (IBM, Armonk, NY, USA).
RESULTS

Sensitization
Repeated cocaine treatment for 5 days significantly increased locomotor activity after the cocaine challenge (day 1 vs. day 5, t=-5.177, df=38, p=0.000, paired t-test). When locomotor activity was measured 1 week later (day 13), this sensitized state was maintained (day 1 vs. day 13, t=-4.293, df=38, p=0.000). However, no significant change in locomotor activity was observed during the 30 min before the cocaine challenge ( Figure 2 ).
Group differences in post-cocaine locomotor activities
We divided the animals into four groups to maintain similar post-cocaine locomotor activity mean values on day 13. No group differences in locomotor activity on days 1 (F=0.224, df=38, p=0.879, ANOVA), 5 (F=0.690, df=38, p=0.564), or 13 (F=0.119, df=38, p=0.948) were observed. However, we found a significant group difference in post-cocaine locomotor activity on day 23 (F=2.883, df=38, p=0.049). The post-hoc test Induction of behavioral sensitization after cocaine treatment. Locomotor activities pre-(for 30 min) and post-(for 60 min) cocaine administration were measured and the average values were plotted on days 1, 5, and 13 (n=39). Pre-cocaine activities were not different between days. Post-cocaine activities increased significantly on day 5, as compared to day 1, and the increase was maintained until day 13. Error bars represent the standard error of mean. *significant difference compared to day 1 at p=0.05. cm discriminated the clozapine group from the vehicle group, while the haloperidol and fluoxetine groups were not discriminated from the vehicle group ( Figure 3A) . We also examined changes in post-cocaine locomotor activity on day 23 from day 5 (sensitized) in each group using a paired t-test. The change was significant in the clozapine group (t=3.259, df=9, p=0.010), but not in the fluoxetine (t= -0.722, df=9, p=0.489), haloperidol (t=-1.535, df=9, p=0.159) or vehicle (t=0.956, df=8, p=0.367) groups. This shows that the sensitized state was altered by clozapine ( Figure 4A ).
Group difference in pre-cocaine locomotor activities
We also examined the pre-cocaine locomotor activities and found no group differences on days 1, 5, and 13. However, on day 23, the pre-cocaine activities differed between groups (F= 3.450, df=38, p=0.027, ANOVA) ( Figure 3B ). Post-hoc test discriminated the clozapine and fluoxetine groups from the vehicle group. Further analysis comparing day 23 pre-cocaine activity to day 5 pre-cocaine activity revealed that the activity is not changed in the clozapine (t=0.038, df=9, p=0.971) and fluoxetine (t=1.019, df=9, p=0.335) groups but increased in the haloperidol (t=-3.162, df=9, p=0.038) and vehicle groups (t=-2.431, df=8, p=0.041). Thus the group difference emanated from the increased activity in the haloperidol and vehicle groups ( Figure 4B ). However the significance disappeared when corrected for the multiple testing.
DISCUSSION
Although the treatment period of 5-days for both cocaine and therapeutic agents is insufficient from a clinical point of view, our previous results definitely indicated the feasibility of this experimental paradigm, and we used a similar one in the present study. Haloperidol-or vehicle-treated groups showed a trend of increase in the pre-cocaine locomotor activity on day 23, compared to day 5. We could not find this effect in our previous experiment. 10 If we assume that the locomotor activity before cocaine challenge reflects the intrinsic dopamine activity, this difference may be due to the difference in the experimental protocol. In the previous experiment, all cocaine injections were performed in the locomotor chambers, while in the present experiment the 2nd to 4th injections were performed in the home cages. Thus on day 23 in the present study, the locomotor chambers might still be a "novel" environment or a kind of stress for the animals, and the endogenous dopaminergic activity would be increased. 12, 13 This increased pre-cocaine activity would make the group difference discernable when the sensitization was further advanced by the challenges on days 5 and 13. Dopaminergic drug haloperidol treatment neither ameliorated nor aggravated the sensitized state in our condition. Fluoxetine, a drug with serotonergic activity, prevented the increase in pre-cocaine locomotor activity. This may be related to the stress-reducing effect of antidepressant or the serotonergic mechanism discussed below.
Although D2 blocking agents can induce depression, a lowdose SDA is indicated in some cases of depression. Ritanserin, a 5-HT2 antagonist, is effective for treating depressive symptoms. 14, 15 In animal models, 5-HT2 blockade has a serotoninaugmenting effect, which has been suggested as the mechanism of the antidepressant effect of SDAs. 16 Thus the SDA and fluoxetine may have common effect in augmenting the serotonergic system and this action without dopamiergic blockade may be related to the partial effect of fluoxetine. Ritanserin partially reversed metamphetamine-induced sensitization. 17 The present results basically replicated our previous findings regarding clozapine. 10 We also confirmed that the recovery from the sensitized state was not achieved by the typical antipsychotics haloperidol. The dose of haloperidol used in our study is in a somewhat high range, 2 mg/kg. Many studies use animal select dose in range of 0.2-2 mg/kg. But the locomotor activity of haloperidol applied group was not low high in our study (Figure 3) . The sedative effect of high dose haloperidol could be therefore excluded. Moreover, our protocol had a sufficient time for wash-out period in order to exclude an acute drug effect. Although antipsychotics inhibit the induction of sensitization and block expression of sensitization when co-administered with the stimulants, typical antipsychotics per se can induce dopaminergic sensitization when given repeatedly. 11 Thus the high-dose haloperidol could reinforce cocaine-induced dopaminergic hypersensitivity. In some groups, tardive dyskinesia (TD) is believed to be a consequence of dopaminergic hypersensitivity induced by longterm D2 blockade. 18, 19 However, its effects were only comparable to the vehicle in the present study. Sensitization is reversed by the combination of serotonergic 5-HT2A blockade and dopaminergic agonist or stimulant. 9 Clozapine has much higher affinity for 5-HT2 receptors than for D2 receptors. We used low-dose clozapine (5 mg/kg), which would have sufficient action on 5-HT2 receptors with little effect on D2 receptors. This may be related to the present result as well as to its effects on TD. However, 5-HT2 blockade alone is insufficient to completely reverse the sensitized state and an unknown mechanism may work for clozapine in this regard. The second-generation antipsychotics other than clozapine, with high affinities for both 5-HT2 and D2 receptors (serotonin-dopamine antagonists, SDAs), are ineffective for treating TD or even induce TD 20 and this suggests that even under the 5-HT2A blockade, D2 blockade would not result in the amelioration of sensitized state.
We found that clozapine and fluoxetine had reversal ability of sensitized state, but the underlying mechanism is unclear. Moreover the relationship between biochemical and behavioral changes are unclear, too. Thus, more studies are necessary in view of biochemical perspectives.
